Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1998 2
2000 3
2001 1
2005 1
2006 2
2009 1
2014 1
2015 4
2016 2
2018 2
2019 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Rha SY, et al. Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875143 Clinical Trial.
Pregnancy and radiation.
Fenig E, Mishaeli M, Kalish Y, Lishner M. Fenig E, et al. Among authors: mishaeli m. Cancer Treat Rev. 2001 Feb;27(1):1-7. doi: 10.1053/ctrv.2000.0193. Cancer Treat Rev. 2001. PMID: 11237773 Review.
ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.
Moskovitz M, Dudnik E, Shamai S, Rotenberg Y, Popovich-Hadari N, Wollner M, Zer A, Gottfried M, Mishaeli M, Rosenberg SK, Onn A, Merimsky O, Urban D, Peled N, Maimon N, Bar J. Moskovitz M, et al. Among authors: mishaeli m. Oncologist. 2022 Feb 3;27(1):e76-e84. doi: 10.1093/oncolo/oyab005. Oncologist. 2022. PMID: 35305096 Free PMC article.
[THE CURRENT APPROACH TO ADVANCED LUNG CANCER].
Gottfried M, Keizman D, Mishaeli M, Maimon Rabinovich N. Gottfried M, et al. Among authors: mishaeli m. Harefuah. 2015 Aug;154(8):521-4, 539-40. Harefuah. 2015. PMID: 26480619 Review. Hebrew.
Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
Ben-Aharon I, Goshen-Lago T, Sternschuss M, Morgenstern S, Geva R, Beny A, Dror Y, Steiner M, Hubert A, Idelevich E, Shulman K, Mishaeli M, Man S, Liebermann N, Soussan-Gutman L, Brenner B. Ben-Aharon I, et al. Among authors: mishaeli m. Oncologist. 2019 Aug;24(8):e696-e701. doi: 10.1634/theoncologist.2018-0351. Epub 2019 Feb 12. Oncologist. 2019. PMID: 30755502 Free PMC article.
A comparison of two dose regimens in pancreatic cancer.
Figer A, Sadikov E, Mishaeli M, Koren R, Gal R, Levin I, Klein B. Figer A, et al. Among authors: mishaeli m. J Chemother. 2000 Oct;12(5):442-5. doi: 10.1179/joc.2000.12.5.442. J Chemother. 2000. PMID: 11128566 Clinical Trial.
Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
Dudnik E, Bar J, Peled N, Bshara E, Kuznetsov T, Cohen AY, Shochat T, Nechushtan H, Onn A, Agbarya A, Moskovitz M, Keren S, Popovits-Hadar N, Urban D, Mishaeli M, Rabinovich NM, Brenner R, Zer A, Rotem O, Roisman LC, Wollner M; Israel Lung Cancer Group. Dudnik E, et al. Among authors: mishaeli m. Clin Lung Cancer. 2019 Jul;20(4):278-286.e1. doi: 10.1016/j.cllc.2019.03.007. Epub 2019 Apr 5. Clin Lung Cancer. 2019. PMID: 31060855
24 results